Continuous Temperature Monitoring Could Detect Febrile Neutropenia

Remote temperature monitoring devices may enable early detection of febrile neutropenia in adults with AML who have ...

MAY 21, 2024

Many Differences in Latest HIV Patient to Achieve HIV Remission With HSCT

A 66-year-old patient living with HIV and acute myeloid leukemia achieved complete remission from both his HIV and ...

JULY 27, 2022

New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML

The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...

MAY 27, 2022

Onureg, Oral Formulation of Azacitidine, Approved for AML

The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid ...

SEPTEMBER 4, 2020

FDA Approves Ivosidenib as First-Line Therapy for AML

The agency reviewed the application for ivosidenib using its Real-Time Oncology Review pilot program.

MAY 3, 2019

Tibsovo Offers Oral Option for IDH1-Positive Relapsed/Refractory AML

The FDA has approved ivosidenib (Tibsovo, Agios) for the treatment of adults with relapsed or refractory acute ...

JULY 22, 2018

FDA Approves Idhifa and RealTime IDH2 Assay for Relapsed or Refractory AML

Celgene's Idhifa was approved to treat adult patients with relapsed or refractory AML who have a specific genetic ...

AUGUST 2, 2017

Quinolones Reduce Infections, Delay Febrile Neutropenia in Relapsed/Refractory AML Patients

Treating patients with relapsed/refractory AML prophylactically with quinolones reduced the incidence of bacteremia ...

JULY 5, 2016